BSEBeryl Drugs LtdHighPositive
Announced Fri, 13 Mar · 15:31 IST

DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹20.20
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.7-1.0+3.9+5.9+1.5+0.5+28.7+21.4-0.5+16.3
Up moveDown movePending
AI summary

Sudhir Sethi, the main Promoter and Director of Beryl Drugs Ltd (DIN: 00090172), has bought 15,000 equity shares of the company through an on-market purchase on March 13, 2026. This acquisition represents 0.29% of the company's share capital. As a result, his total holding has increased from 4,55,143 shares (18.98%) to 4,70,143 shares (19.27%). The disclosure was filed under SEBI's Insider Trading Regulations, as required for promoter share purchases.

Likely market impact

This is a small insider buy by the promoter, which is generally viewed as a mildly positive signal showing promoter confidence in the company. However, the size of the purchase (just 0.29%) is too small to materially shift shareholder sentiment or drive significant stock price movement.